The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 27, 2026

Filed:

Apr. 28, 2017
Applicant:

Genome Research Limited, Hinxton, GB;

Inventors:

Serena Nik-Zainal, Hinxton, GB;

Helen Davies, Hinxton, GB;

Dominik Glodzik, Hinxton, GB;

Sandro Morganella, Hinxton, GB;

Assignee:

Genome Research Limited, Cambridge, GB;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G16B 20/10 (2019.01); C12Q 1/6886 (2018.01); G16B 5/00 (2019.01); G16B 10/00 (2019.01); G16B 20/00 (2019.01); G16B 25/10 (2019.01); G16B 30/00 (2019.01); G16B 50/00 (2019.01);
U.S. Cl.
CPC ...
G16B 20/10 (2019.02); C12Q 1/6886 (2013.01); G16B 5/00 (2019.02); G16B 10/00 (2019.02); G16B 20/00 (2019.02); G16B 25/10 (2019.02); G16B 30/00 (2019.02); G16B 50/00 (2019.02); C12Q 2537/165 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract

The invention provides a method of characterising a DNA sample obtained from a tumour, the method including the steps of: determining the presence or absence of a plurality of base substitution signatures, rearrangement signatures and indel signatures in the sample and copy number profiles for the sample; generating, from the presence or absence of said plurality of base substitution signatures, rearrangement signatures and indel signatures and the copy number profile for the sample, a probabilistic score; and based on said probabilistic score, identifying whether said sample has a high or low likelihood of being homologous recombination (HR)-deficient. Identification of a tumour as HR-deficient may be used to inform treatment choices, for example treatment with a PARP inhibitor or platinum therapy or an anthracycline.


Find Patent Forward Citations

Loading…